UK-based psychedelic drug developer Compass Pathways highlighted a few milestones in its Q3 financial results for the period ended September 30, 2022, which include publishing results of Phase II trials COMP360—Compass’ psilocybin therapy—for treatment-resistant depression (TRD) in a peer-reviewed journal and completed its long-term follow-up study, launching an investigator-led study for autism spectrum disorder in adults, and receiving ten patents to date.
Compass also outlined some targets for the upcoming quarters, which include launching the Phase III trial of COMP360 for TRD by December 2022, progressing in its ongoing Phase II trial of the candidate for anorexia nervosa and post-traumatic stress disorder (PTSD), and exploring other disease indications for COMP360.
Compass reported a net loss per share of USD 0.43 in Q3 2022, beating analysts’ expectations by 12%. However, the firm’s net losses increased by 17% YoY to USD 18.4 million in Q3 2022 due to higher operating expenses.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.